The 56th American Society of Hematology (ASH) annual meeting has reported 171 abstracts about hematopoietic stem cell transplantation (HSCT) for treating lymphoma,including 102 autologous HSCT (auto-HSCT) and 69 allogeneic HSCT (allo-HSCT),which mainly covered clinical effects of HSCT on patients with relapse/refractory Hodgkin lymphoma and high risk,aggressive non-Hodgkin lymphoma,as well as the impact factors such as the best time for transplantation,improvement of conditioning regimen,applying target chemotherapy prior to transplantation,preventing graft-versus-host disease (GVHD),and predictors for transplantation outcome.